Displaying drugs 14901 - 14925 of 15113 in total
Reproxalap
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
Investigational
Matched Description: … Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and …
RUS 3108
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Investigational
Matched Description: … the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and …
OSI-7904L
OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.
Investigational
Matched Description: … liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and …
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
2,5-Dimethoxy-4-(n)-propylthiophenethylamine
Experimental
Illicit
4-Bromo-2,5-dimethoxyphenethylamine
Experimental
Illicit
R048-8071
Experimental
4-Phenylbutylamine
Experimental
2,3-Difluorobenzyl Alcohol
Experimental
Phenethylamine
Experimental
Soneclosan
Experimental
3-Phenylpropylamine
Experimental
2,5-di-tert-butylhydroquinone
Experimental
(S)-4-Nitrostyrene oxide
Experimental
p-Cumylphenol
Experimental
5-PENTYL-2-PHENOXYPHENOL
Experimental
N-methyl-1-(2-thiophen-2-ylphenyl)methanamine
Experimental
Displaying drugs 14901 - 14925 of 15113 in total